Citations

Clear

1134 citation(s) found for "Yan, Di".

Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction
Benfari, Giovanni , Antoine, Clémence , Thapa, Prabin , Topilsky, Yan , Rossi, Andrea , Pislaru, Sorin V. , Enriquez‐Sarano, Maurice , Topilsky, Yan , Miller, Wayne L. , Pislaru, Sorin, Sabbah, Michael S. , Enriquez-Sarano, Maurice , Benfari, Giovanni , Topilsky, Yan , Michelena, Héctor I.

Mayo Clinic

Circulation | May 23, 2019 | Volume: 140 | Issue: 3 | Pages: 196-206

10.1161/circulationaha.118.038946 | PMID 31117814 Get It

Background: Functional tricuspid regurgitation (FTR) is common in heart failure with reduced ejection fraction and mostly consequent to pulmonary hypertension. However, the intrinsic clinical implications of FTR are not fully understood. Methods: The cohort of all Mayo Clinic patients from 2003 to 2011 diagnosed with heart failure stage B-C and ejection fraction<50%, with FTR grading and systolic pulmonary artery pressure estimation by Doppler echocardiography was identified and outcomes were analyzed. Patients with pacemakers/defibrillators, organic valve disease, or previous valve surgery were excluded. The primary outcome measure was overall mortality (censored at implantation of a defibrillator, ventricular assist device, or cardiac transplantation), adjusting for clinical and echocardiographic associates with mortality and major comorbidities. Results: Among 13 026 patients meeting inclusion criteria, FTR was detected in 88% (N=11 507: 33% trivial, 32% mild, 17% moderate, and 6% severe), aged 68±14 years, 35% women, ejection fraction 36±10%, systolic pulmonary artery pressure 41±14 mm Hg with 20% atrial fibrillation. Covariates independently associated with FTR included elevated systolic pulmonary artery pressure, older age, female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P <0.0001). FTR was independently associated with more dyspnea, impaired kidney function, and lower cardiac output ( P <0.003 for all). For long-term outcome, higher FTR degree compared with trivial tricuspid regurgitation was independently associated with higher mortality (adjusted hazard ratios 1.09 [1.01-1.17] for mild FTR, 1.21 [1.11-1.33] for moderate FTR and 1.57 [1.39-1.78] for severe FTR); hence, 5-year survival was substantially lower with increasing severity of functional FTR, 68±1% for trivial FTR, 58±2% for mild FTR, 45±2% for moderate FTR, and 34±4% for severe FTR. Conclusions: In this large cohort of patients with heart failure with reduced ejection fraction, FTR was common and independently associated with pulmonary hypertension, atrial fibrillation, and more severe heart failure presentation. Long-term, higher FTR severity is associated with considerably worse survival, independently of baseline characteristics. Given these untoward outcomes associated with FTR in patients with heart failure with reduced ejection fraction, clinical trials should be directed at testing FTR treatment.
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Luchtel, Rebecca A. , Zimmermann, Michael T. , Hu, Guangzhen , Dasari, Surendra , Jiang, Manli, Jacobs, Hailey K., Zeng, Yu , Hundal, Tanya , Lee, Jeong‐Heon , Eckloff, Bruce W., Yan, Huihuang , Gaonkar, Krutika S. , Tian, Shulan , Ye, Zhenqing, Sidhu, Jagmohan S. , Jiang, Liuyan , Voss, Jesse S. , Link, Brian K. , Syrbu, Sergei , Ördög, Tamás , Kocher, Jean‐Pierre , Ansell, Stephen M. , Lee, Jeong-Heon , Jiang, Liuyan , Ordog, Tamas , Cerhan, James R , Feldman, Andrew L , Link, Brian K , Zimmermann, Michael T , Syrbu, Sergei , Oishi, Naoki , Rech, Karen L. , Ketterling, Rhett P. , Kadin, Marshall E. , Facchetti, Fabio , Bennani, N. Nora , Slager, Susan L. , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | May 18, 2019 | Volume: 133 | Issue: 26 | Pages: 2776-2789

10.1182/blood.2019000626 | PMID 31101622 Get It

AbstractAnaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked genetic heterogeneity. ALCLs are broadly classified as being anaplastic lymphoma kinase (ALK)+ or ALK−, based on the presence or absence of ALK rearrangements. Exome sequencing of 62 T-NHLs identified a previously unreported recurrent mutation in the musculin gene, MSCE116K, exclusively in ALK− ALCLs. Additional sequencing for a total of 238 T-NHLs confirmed the specificity of MSCE116K for ALK− ALCL and further demonstrated that 14 of 15 mutated cases (93%) had coexisting DUSP22 rearrangements. Musculin is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with other bHLH proteins to regulate lymphocyte development. The E116K mutation localized to the DNA binding domain of musculin and permitted formation of musculin–bHLH heterodimers but prevented their binding to authentic target sequence. Functional analysis showed MSCE116K acted in a dominant-negative fashion, reversing wild-type musculin-induced repression of MYC and cell cycle inhibition. Chromatin immunoprecipitation–sequencing and transcriptome analysis identified the cell cycle regulatory gene E2F2 as a direct transcriptional target of musculin. MSCE116K reversed E2F2-induced cell cycle arrest and promoted expression of the CD30–IRF4–MYC axis, whereas its expression was reciprocally induced by binding of IRF4 to the MSC promoter. Finally, ALCL cells expressing MSCE116K were preferentially targeted by the BET inhibitor JQ1. These findings identify a novel recurrent MSC mutation as a key driver of the CD30–IRF4–MYC axis and cell cycle progression in a unique subset of ALCLs.
β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies
Shahin, Mohamed H. , Rouby, Nihal El , Conrado, Daniela J., González, Daniel , Lobmeyer, Maximilian T. , Beitelshees, Amber L. , Boerwinkle, Eric , Gums, John G. , Chapman, Arlene B. , Pepine, Carl J. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

The Journal of Clinical Pharmacology | May 15, 2019 | Volume: 59 | Issue: 11 | Pages: 1462-1470

10.1002/jcph.1443 | PMID 31090079 Get It

Abstractβ‐Blockers’ heart rate (HR)‐lowering effect is an important determinant of the effectiveness for this class of drugs, yet it is variable among β‐blocker–treated patients. To date, genetic studies have revealed several genetic signals associated with HR response to β‐blockers. However, these genetic signals have not been consistently replicated across multiple independent cohorts. Here we sought to use data from 3 hypertension clinical trials to validate single‐nucleotide polymorphisms (SNPs) previously associated with the HR response to β‐blockers. Using linear regression analysis, we investigated the effects of 6 SNPs in 3 genes, including ADRB1, ADRB2, and GNB3, relative to the HR response following β‐blocker used in the PEAR (n = 757), PEAR‐2 (n = 368), and INVEST (n = 1401) trials, adjusting for baseline HR, age, sex, and ancestry. Atenolol was used in PEAR and INVEST, and metoprolol was used in PEAR‐2. We found that rs1042714 and rs1042713 in ADRB2 were significantly associated with HR response to both β‐blockers in whites (rs1042714 C‐allele carriers, meta‐analysis β = –0.95 beats per minute [bpm], meta‐analysis P = 3×10–4; rs1042713 A‐allele carriers, meta‐analysis β = –1.15 bpm, meta‐analysis P = 2×10–3). In conclusion, the results of our analyses provide strong evidence to support the hypothesis that rs1042714 and rs1042713 in the ADRB2 gene are important predictors of HR response to cardioselective β‐blockade in hypertensive patient cohorts.
Onset of Telomere Dysfunction and Fusions in Human Ovarian Carcinoma
Huda, Nazmul , Xu, Yan , Bates, Alison M. , Rankin, Deborah A., Kannan, Nagarajan , Gilley, David, Kannan, Nagarajan

Mayo Clinic

Cells | May 13, 2019 | Volume: 8 | Issue: 5 | Pages: 414

10.3390/cells8050414 | PMID 31060240 Get It

Telomere dysfunction has been strongly implicated in the initiation of genomic instability and is suspected to be an early event in the carcinogenesis of human solid tumors. Recent findings have established the presence of telomere fusions in human breast and prostate malignancies; however, the onset of this genomic instability mechanism during progression of other solid cancers is not well understood. Herein, we explored telomere dynamics in patient-derived epithelial ovarian cancers (OC), a malignancy characterized by multiple distinct subtypes, extensive molecular heterogeneity, and widespread genomic instability. We discovered a high frequency of telomere fusions in ovarian tumor tissues; however, limited telomere fusions were detected in normal adjacent tissues or benign ovarian samples. In addition, we found relatively high levels of both telomerase activity and hTERT expression, along with anaphase bridges in tumor tissues, which were notably absent in adjacent normal ovarian tissues and benign lesions. These results suggest that telomere dysfunction may occur early in ovarian carcinogenesis and, importantly, that it may play a critical role in the initiation and progression of the disease. Recognizing telomere dysfunction as a pervasive feature of this heterogeneous malignancy may facilitate the future development of novel diagnostic tools and improved methods of disease monitoring and treatment.
Abstract C61: High fat triggers oncogenic K-Ras activity and a COX2 dependent feed-forward loop to induce pancreatic ductal adenocarcinoma development
Philip, Bincy, Daniluk, Jarek, Liu, Yan , Gomez, Sobeyda, Ji, Baoan , Haojie, Huang, Fleming, Jason B. , Logsdon, Craig D. , Cruz‐Monserrate, Zobeida , Roland, Christina Lynn , Chatterjee, Deyali , Haojie, Huang, Wang, Huamin

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: C61-C61

10.1158/1940-6215.prev-13-c61 Get It

Abstract Obesity is a risk factor for Pancreatic Ductal Adenocarcinoma (PDAC), but the molecular mechanisms involved are unclear. Oncogenic mutation of K-Ras occurs early and nearly universally in patients with this disease. However, recent evidence indicates that oncogenic Ras is not fully active and for activity to surpass the threshold required to engage a Ras-inflammation feed-forward loop, it requires a stimulus. We hypothesized that high-fat intake acts as an inflammatory stimulus, increasing K-Ras activity and that cyclooxygenase -2 (COX2) expression is required in the inflammatory loop. LSL-K-Ras mice were crossed with elastase-CreER (acinar cell-specific) or Pdx1-Cre (pancreatic cell-specific) to “knock-in” expression of oncogenic K-Ras. Additionally, acinar cell-specific -Ras mice were crossed with COX2 conditional knockout mice. All mice were fed isocaloric diets with different amounts of fat and a COX2 inhibitor was administered to some acinar cell-specific -Ras mice. Pancreata were analyzed for Ras activity, Phospho-ERK levels, inflammation, fibrosis, PanIN and PDAC development. We observed that consumption of a high fat diet (HFD) led to increased K-Ras activity, PanIN formation, fibrotic stroma and PDAC development compared to a control diet. Additionally, we observed a significant reduction in the survival of mice fed a HFD. Genetic deletion of COX2 in acinar cells and COX2 systemic inhibition prevented the HFD-induced effects in acinar cell-specific -Ras mice. These findings indicated that a HFD stimulates activation of oncogenic K-Ras and initiates an inflammatory feed-forward loop requiring the expression of COX2 leading to pancreatic inflammation, fibrosis, PanINs and PDAC. This mechanism may explain the PDAC risks associated with consumption of a HFD. Citation Format: Bincy Philip, Christina L. Roland, Jarek Daniluk, Yan Liu, Deyali Chatterjee, Sobeyda Berenice Gomez, Baoan Ji, Huang Haojie, Huamin Wang, Jason B. Fleming, Craig D. Logsdon, Zobeida Cruz-Monserrate. High fat triggers oncogenic K-Ras activity and a COX2 dependent feed-forward loop to induce pancreatic ductal adenocarcinoma development. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr C61.
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta‐Blockers in European Americans
Singh, Sonal , Rouby, Nihal El , McDonough, Caitrin W. , Bailey, Kent R. , Boerwinkle, Eric , Chapman, Arlene B. , Gums, John G. , Johnson, Julie A. , Chapman, Arlene B. , Turner, Stephen T. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Clinical and Translational Science | April 29, 2019 | Volume: 12 | Issue: 5 | Pages: 497-504

10.1111/cts.12643 | PMID 31033190 Get It

European Americans (EA) have a better antihypertensive response to β‐blockers when compared with African Americans, albeit with some variability. We undertook a genomewide association study to elucidate the underlying genetic determinants in EA contributing to this variability in blood pressure (BP) response. A discovery genomewide association study of change in BP post–metoprolol treatment was performed in EA participants (n = 201) from the Pharmacogenomic Evaluation of Antihypertensive Responses‐2 (PEAR‐2) study and tested for replication in the atenolol‐treated EA from the PEAR study (n = 233). Rs294610 in the FGD5, which encodes for FYVE, RhoGEF and PH Domain Containing 5, (expression quantitative trait loci for FGD5 in the small intestine) was significantly associated with increased diastolic BP response to β‐blockers in the PEAR‐2 study (P = 3.41 × 10−6, β = −2.70) and replicated (P = 0.01, β = −1.17) in the PEAR study. Post–meta‐analysis of these studies, an additional single nucleotide polymorphism rs45545233 in the SLC4A1, encoding for Solute Carrier Family 4 Member 1, (expression quantitative trait loci for dual specificity phosphatase 3 in the artery tibial) was identified that was significantly associated with a poor response to β‐blockers (P = 3.43 × 10−6, β = 4.57) and was replicated in the atenolol add‐on cohort (P = 0.007, β = 4.97). We identified variants in FGD5 and SLC4A1, which have been previously cited as candidate genes for hypertension, to be associated with a β‐blocker BP response in EA. Further elucidation is warranted of the underlying mechanisms of these variants and genes by which they influence the BP response to β‐blockers.
PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
Chamberlain, Alanna M. , Shaw, Kathryn M., Bian, Jiang , Song, Wen‐Liang , Guhl, Emily , Shah, Rashmee U. , Puro, Jon , Pawloski, Pamala A. , Margolis, Karen L. , Chamberlain, Alanna M , Bian, Jiang , Shah, Rashmee U , Gong, Yan , Linton, MacRae F. , Fonseca, Vivian , Price‐Haywood, Eboni G. , King, Jordan B. , Shenkman, Elizabeth , Hernandez, Adrian F. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | April 25, 2019 | Volume: 8 | Issue: 9 | Pages: No page available

10.1161/jaha.118.011246 | PMID 31020929 Get It

Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibitors, in addition to standard therapies, according to cardiovascular risk status. Methods and Results Data were obtained from 18 health systems with data marts within the National Patient‐Centered Clinical Research Network (PCORnet) using a common data model. Participating sites identified >17.5 million adults, of whom 3.6 million met study criteria. Patients were categorized into 3 groups: (1) dyslipidemia, (2) untreated LDL ≥130 mg/dL, and (3) coronary artery disease or coronary heart disease. Demographics, comorbidities, estimated 10‐year atherosclerotic cardiovascular disease risk, and lipid‐lowering pharmacotherapies were summarized for each group. Participants’ average age was 62 years, 50% were female, and 11% were black. LDL cholesterol ranged from 85 to 151 mg/dL. Among patients in groups 1 and 3, 54% received standard lipid‐lowering therapies and a PCSK9 inhibitor was prescribed in <1%. PCSK9 inhibitor prescribing was greatest for patients with coronary artery disease or coronary heart disease and, although prescribing increased during the study period, overall PCSK9 inhibitor prescribing was low. Conclusions We successfully used electronic health record data from 18 PCORnet data marts to identify >3.6 million patients meeting criteria for 3 patient groups. Approximately half of patients had been prescribed lipid‐lowering medication, but <1% were prescribed PCSK9 inhibitors. PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.
Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Xing, Deyin , Zheng, Gang , Pallavajjala, Aparna, Schoolmeester, J. Kenneth , Liu, Yuehua , Haley, Lisa , Hu, Yan , Liu, Li , Logan, Lisa, Lin, Yuan, Pearce, Kathryn E., Sattler, Christopher A., Tsai, Ya Chea, Vang, Russell , Hung, Chien‐Fu , Wu, T.‐C. , Ronnett, Brigitte M., Logan, Lisa

Mayo Clinic

Clinical Cancer Research | April 22, 2019 | Volume: 25 | Issue: 14 | Pages: 4516-4529

10.1158/1078-0432.ccr-18-4278 | PMID 31010836 Get It

Abstract Purpose: Choriocarcinoma is most commonly gestational (androgenetic or biparental) but can be of germ cell origin or can develop as a component of a somatic neoplasm (genetically related to the patient). The latter type are aggressive neoplasms for which the underlying genetic alterations are not well characterized. Experimental Design: To investigate the relationship between the different components of somatic neoplasms with choriocarcinomatous elements, the genetic differences between gestational and nongestational tumors, and identify potential targetable alterations, we analyzed 23 samples from 11 tumors, including five gynecologic-type somatic neoplasms with choriocarcinomatous differentiation (two to three different components each) and six pure choriocarcinomas, for somatic mutations, single-nucleotide polymorphisms, and PD-L1 expression. Results: In mixed tumors, gynecologic-type carcinoma components demonstrated lineage-characteristic and lineage-specific alterations, with choriocarcinomatous components sharing some of these as well as demonstrating novel alterations, supporting a clonal relationship with divergent differentiation of the choriocarcinoma from the somatic carcinoma. TP53 mutation only occurred in nongestational tumors. Diffuse PD-L1 expression was characteristic of choriocarcinoma in both pure and mixed tumors but not seen in the gynecologic-type carcinoma components. Conclusions: Given that the somatic carcinomatous and choriocarcinomatous components of mixed tumors have distinct genetic alterations and biomarker expression, separate analysis of these components is required to guide targeted therapy. High PD-L1 expression suggests a role for checkpoint inhibitor–based immunotherapy in tumors with a choriocarcinoma component. The underlying mechanisms by which cancer stem cells reprogram and initiate trophoblastic retrodifferentiation in some somatic tumors warrant further investigation.
Hypereosinophilia in a Patient with Metastatic Non-Small-Cell Lung Cancer Treated with Antiprogrammed Cell Death 1 (anti-PD-1) Therapy
Lou, Yanyan , Marin‐Acevedo, Julian A. , Vishnu, Prakash , Dholaria, Bhagirathbhai , Soyano, Aixa , Knutson, Keith L. , Manochakian, Rami , Dholaria, Bhagirathbhai R , Vishnu, Prakash , Soyano, Aixa , Luo, Yan , Zhang, Yan , Knutson, Keith L.

Mayo Clinic

Immunotherapy | April 4, 2019 | Volume: 11 | Issue: 7 | Pages: 577-584

10.2217/imt-2018-0128 | PMID 30943864 Get It

Elevated intracellular trypsin exacerbates acute pancreatitis and chronic pancreatitis in mice
Zhan, Xianbao , Wan, Jianhua , Zhang, Guowei , Song, Lele , Gui, Fu , Zhang, Yuebo , Li, Yinghua , Guo, Jia , Dawra, Rajinder , Saluja, Ashok K. , Haddock, Ashley , Zhang, Lizhi , Bi, Yan , Ji, Baoan , Haddock, Ashley N, Zhan, Xianbao , Gui, Fu

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 3, 2019 | Volume: 316 | Issue: 6 | Pages: G816-G825

10.1152/ajpgi.00004.2019 | PMID 30943050 Get It

Intra-acinar trypsinogen activation occurs in the earliest stages of pancreatitis and is believed to play important roles in pancreatitis pathogenesis. However, the exact role of intra-acinar trypsin activity in pancreatitis remains elusive. Here, we aimed to examine the specific effects of intra-acinar trypsin activity on the development of pancreatitis using a transgenic mouse model. This transgenic mouse model allowed for the conditional expression of a mutant trypsinogen that can be activated specifically inside pancreatic acinar cells. We found that expression of this active mutated trypsin had no significant effect on triggering spontaneous pancreatitis. Instead, several protective compensatory mechanisms, including SPINK1 and heat shock proteins, were upregulated. Notably, these transgenic mice developed much more severe acute pancreatitis, compared with control mice, when challenged with caerulein. Elevated tissue edema, serum amylase, inflammatory cell infiltration and acinar cell apoptosis were dramatically associated with increased trypsin activity. Furthermore, chronic pathological changes were observed in the pancreas of all transgenic mice, including inflammatory cell infiltration, parenchymal atrophy and cell loss, fibrosis, and fatty replacement. These changes were not observed in control mice treated with caerulein. The alterations in pancreata from transgenic mice mimicked the histological changes common to human chronic pancreatitis. Taken together, we provided in vivo evidence that increased intra-acinar activation of trypsinogen plays an important role in the initiation and progression of both acute and chronic pancreatitis. NEW & NOTEWORTHY Trypsinogen is activated early in pancreatitis. However, the roles of trypsin in the development of pancreatitis have not been fully addressed. Using a genetic approach, we showed trypsin activity is critical for the severity of both acute and chronic pancreatitis.